Phoenix Holdings Ltd. Makes New $18.03 Million Investment in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Share on StockTwits

Phoenix Holdings Ltd. purchased a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 192,933 shares of the biopharmaceutical company’s stock, valued at approximately $18,026,000. Phoenix Holdings Ltd. owned about 0.09% of Alexion Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALXN. We Are One Seven LLC grew its stake in shares of Alexion Pharmaceuticals by 5.7% during the 2nd quarter. We Are One Seven LLC now owns 1,586 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 86 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Alexion Pharmaceuticals by 13.2% in the 2nd quarter. Signaturefd LLC now owns 822 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 96 shares during the last quarter. Investors Research Corp boosted its holdings in shares of Alexion Pharmaceuticals by 52.0% in the 3rd quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 104 shares during the last quarter. Synovus Financial Corp boosted its holdings in shares of Alexion Pharmaceuticals by 4.6% in the 3rd quarter. Synovus Financial Corp now owns 2,391 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 106 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Alexion Pharmaceuticals by 6.5% in the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,810 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 111 shares during the last quarter. 91.60% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ ALXN traded up $1.40 during mid-day trading on Wednesday, reaching $115.45. The company had a trading volume of 1,659,674 shares, compared to its average volume of 1,783,520. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.45 and a current ratio of 3.98. Alexion Pharmaceuticals, Inc. has a one year low of $92.56 and a one year high of $141.86. The firm has a market cap of $25.21 billion, a price-to-earnings ratio of 16.28, a PEG ratio of 1.08 and a beta of 1.67. The business’s 50-day simple moving average is $107.89 and its 200 day simple moving average is $113.10.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the previous year, the business posted $2.02 earnings per share. The business’s revenue for the quarter was up 23.0% on a year-over-year basis. On average, sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.43 EPS for the current year.

Several equities research analysts have recently commented on the company. Evercore ISI reissued a “buy” rating and issued a $145.00 price objective on shares of Alexion Pharmaceuticals in a report on Sunday, November 17th. Royal Bank of Canada reissued a “buy” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, September 18th. BMO Capital Markets assumed coverage on Alexion Pharmaceuticals in a report on Thursday, September 12th. They issued an “outperform” rating and a $149.00 price objective for the company. BidaskClub raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, November 25th. Finally, Cowen reaffirmed a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $156.37.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: Preferred Stock

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.